Qlucore, Nebion Collaborate
News Feb 07, 2014
The start of 2014 will see Qlucore and Nebion AG working together to promote their two products Qlucore Omics Explorer and Genevestigator.
Qlucore Omics Explorer is a next-generation bioinformatics software program which is extremely fast and allows the user to explore and analyse high-dimensional data sets interactively and in real time. Qlucore Omics Explorer has proved to be hugely beneficial to researchers in the life science and biotech industries when it comes to analysing big data.
Nebion creates innovative systems to extract high value information from the world's genomic data for biotechnology and personalized medicine. Its Genevestigator is a high-performance Web platform which deeply integrates expression data and curated sample annotations. This allows systematic screening of the database for genes that have unique expression properties and validation of target and biomarker genes by checking how they respond to thousands of experimental conditions.
"Nebion complements the Qlucore product offering perfectly by enabling a web based systematic screening of genes across many thousand experiments, so it makes perfect sense to work together to provide a broader solution to our clients. We're excited to be jointly promoting our complementary solutions to help researchers get better results, quickly," says Carl-Johan Ivarsson, CEO Qlucore.
Speaking on the new relationship between the two companies, Dr Philip Zimmermann, CEO Nebion commented, "I got to know Qlucore Omics Explorer a few years ago and I have become convinced that it's one of the best tools to find patterns in data and for biomarker discovery. It is very user-friendly but at the same time statistically robust."
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE
Genetic Variations in the Lungs Identify COPD RiskNews
Developmental genetic variations in the anatomy of the lung could indicate people at risk of COPD later in life, a study suggests.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE